Magnetic resonance imaging features of small-duct primary sclerosing cholangitis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Purpose To evaluate the biliary tree and hepatic parenchymal findings on magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) in small-duct primary sclerosing cholangitis (SD-PSC).Methods Thirty-nine patients with biopsy-proven primary sclerosing cholangitis (PSC) without any bile duct abnormality on MRCP (n = 15) or ERCP (n = 24) at the time of diagnosis were identified. Follow-up MRCP was available in 36/39 patients (12/15 Baseline MRCP group and 24 Baseline ERCP group). Two radiologists in consensus assessed the MRI/MRCP findings. The baseline MRI/MRCP of 15 SD-PSC patients was compared with MRI/MRCP of 15 normal healthy potential liver donors (Control group). Comparisons were made between SD-PSC patients and the Control group, and between baseline and follow-up MRI/MRCP findings in the SD-PSC patients.Results In the 15 Baseline MRCP SD-PSC subjects, the biliary tree was normal with a trend of larger bile ducts compared to the Control group. Periductal enhancement (arterial phase: 70%, 7/10; delayed phase: 90%, 9/10), heterogeneous parenchymal signal on T2-weighted (53%, 8/15) and post contrast-enhanced images (70%, 7/10), and enlarged periportal lymph nodes (73%, 11/15) were frequently present in patients with SD-PSC. Eight (33%) of 24 SD-PSC patients who had normal MRCP at baseline MRCP or initial follow-up MRCP after normal baseline ERCP showed large-duct PSC (LD-PSC) features on follow-up and the 10-year cumulative incidence for progression to LD-PSC rate was 8.5%.Conclusion SD-PSC patients have a normal biliary tree but frequently have peribiliary enhancement, abnormal parenchymal signal intensity, and periportal lymphadenopathy. One-third shows progression to LD-PSC on follow-up.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even though the cholangiographic appearance of bile ducts is normal in patients with small duct PSC, other abnormal findings may be seen on MRI which can increase clinical suspicion for the disease.These include periductal enhancement, heterogeneous parenchymal signal on T2-weighted and post contrast-enhanced images, enlarged gallbladder and enlarged periportal lymph nodes.52”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [52]
Citations
Cites
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Primary Sclerosing Cholangitis
Lazaridis, K. N., & LaRusso, N. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1506330 · Cited by 505 · cited 3×
“1 3 of sclerosing cholangitis, including choledocholithiasis, chronic bacterial cholangitis, and immunoglobulin G4 (IgG4)-associated cholangitis must be excluded to confidently diagnose PSC [1, 2].”
BackgroundUpper abdominal lymph nodes: criteria for normal size determined with CT.
Dorfman, R. E., Alpern, M. B., Gross, B. H., & Sandler, M. A. (1991) · Radiology · doi:10.1148/radiology.180.2.2068292 · Cited by 348 · cited 2×
“S, 13 years of abdominal radiology experience) in consensus evaluated the MRI/MRCP images of SD-PSC patients and Control group for the following features: periductal enhancement on arterial phase and delayed phases [10]; presence/ absence of biliary stones; presence/absence of hepatic surface nodularity; T2W and DWI p…”
BackgroundThe natural history of small-duct primary sclerosing cholangitis
Björnsson, E., Olsson, R., Bergquist, A., Lindgren, S., Braden, B., Chapman, R. W., Boberg, K. M., & Angulo, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.042 · Cited by 305 · cited 4×
“[4], which reported a progression ratio of 22.”
BackgroundInfluentialNakanuma, Y., Hoso, M., Sanzen, T., & Sasaki, M. (1997) · Microscopy Research and Technique · doi:10.1002/(sici)1097-0029(19970915)38:6<552::aid-jemt2>3.0.co;2-h · Cited by 281 · cited 2×
“The “small bile ducts” which include the septal ducts, interlobular ducts, and bile ductules usually are not identified on imaging studies as their diameter is less than 400μm [23] which is below the resolution of current imaging techniques.”
BackgroundPonsioen, C. Y., Vrouenraets, S. M. E., Prawirodirdjo, W., Rajaram, R., Rauws, E. A. J., Mulder, C. J. J., Reitsma, J. B., Heisterkamp, S. H., & Tytgat, G. N. J. (2002) · Gut · doi:10.1136/gut.51.4.562 · Cited by 268
Small-duct primary sclerosing cholangitis: a long-term follow-up study
Angulo, P., Maor-Kendler, Y., & Lindor, K. D. (2002) · Hepatology · doi:10.1053/jhep.2002.33202 · Cited by 213 · cited 2×
“In about 5-10% of PSC patients only small intrahepatic bile ducts are affected [19, 20].”
BackgroundPatients with small duct primary sclerosing cholangitis have a favourable long term prognosis
Björnsson, E., Boberg, K. M., Cullen, S., Fleming, K., Clausen, O. P., Fausa, O., Schrumpf, E., & Chapman, R. W. (2002) · Gut · doi:10.1136/gut.51.5.731 · Cited by 207 · cited 2×
“In about 5-10% of PSC patients only small intrahepatic bile ducts are affected [19, 20].”
BackgroundCirrhosis: Modified Caudate–Right Lobe Ratio
Awaya, H., Mitchell, D. G., Kamishima, T., Holland, G., Ito, K., & Matsumoto, T. (2002) · Radiology · doi:10.1148/radiol.2243011495 · Cited by 196
Gallbladder disease in patients with primary sclerosing cholangitis
Said, K., Glaumann, H., & Bergquist, A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.019 · Cited by 193 · cited 2×
“Mean follow-up (years [range]) 5 [1–15] 13 [2-32] 11 [1-32] NA”
Result
Cited by
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Ponsioen, C. Y., Assis, D. N., Boberg, K. M., Bowlus, C. L., Deneau, M., Thorburn, D., Aabakken, L., Färkkilä, M., Petersen, B., Rupp, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.046 · Cited by 95
Venkatesh, S. K., Welle, C. L., Miller, F. H., Jhaveri, K. S., Ringe, K. I., Eaton, J. E., Bungay, H. K., Arrivé, L., Ba‐Ssalamah, A., Grigoriadis, A., et al. (2021) · European Radiology · doi:10.1007/s00330-021-08147-7 · Cited by 90
Self-citationPrimary sclerosing cholangitis
Manns, M. P., Bergquist, A. M., Karlsen, T. H., Levy, C., Muir, A. J., Ponsioen, C. Y., Trauner, M., Wong, G. L., & Younossi, Z. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00600-x · Cited by 81
“Small-duct PSC is generally thought to represent an earlier stage of PSC, with rates of progression to large-duct PSC of 33% and 55% reported in two observational studies 125,126 .”
Primary sclerosing cholangitis: review for radiologists
Morgan, M. A., Khot, R., Sundaram, K. M., Ludwig, D. R., Nair, R. T., Mittal, P., Ganeshan, D., & Venkatesh, S. K. (2022) · Abdominal Radiology · doi:10.1007/s00261-022-03655-6 · Cited by 31
“If the disease progresses, it does so by first converting to large duct PSC, which can occur in 33–55% of cases [20, 21].”
BackgroundSelf-citationThe 2024 diagnostic criteria for primary sclerosing cholangitis
Naitoh, I., Isayama, H., Akamatsu, N., Mizuno, S., Fujisawa, T., Nakamoto, N., Nakai, Y., Umetsu, S., Suzuki, M., Yagi, S., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02265-5 · Cited by 22
“Two recent studies reported progression to large duct PSC in 33% and 55% of small duct PSC during follow-up [16, 17].”
Recent advances in the treatment of primary sclerosing cholangitis
Bjornsson, E. S., & Kalaitzakis, E. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1860751 · Cited by 20
“Recent radiological follow-up studies have shown that approximately one third of patients found originally to have small duct PSC in a study from the US [28] and 55% in a study from Europe [29] devel-”
BackgroundMR elastography in primary sclerosing cholangitis: a pictorial review
Welle, C. L., Navin, P. J., Olson, M. C., Hoodeshenas, S., Torbenson, M. S., & Venkatesh, S. K. (2022) · Abdominal Radiology · doi:10.1007/s00261-022-03529-x · Cited by 9
“Small duct PSC can demonstrate normal morphology on MRCP and MRE; however, some cases may demonstrate normal MRCP but with increased stiffness [26].”
BackgroundSelf-citationClinics in diagnostic imaging (219)
Chong, J. K., Nah, C. Y., & Low, H. M. (2024) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2022-121 · Cited by 9
“[11] .”
BackgroundAutoimmune Disorders of the Liver and Biliary Tract
Anderson, C. M., Welle, C. L., Ludwig, D. R., Anderson, M., Khot, R., Itani, M., Zulfiqar, M., Torbenson, M. S., & Venkatesh, S. K. (2025) · Radiographics · doi:10.1148/rg.240126 · Cited by 8
Self-citationVenkatesh, S. K., Welle, C. L., Miller, F. H., Jhaveri, K. S., Ringe, K. I., Eaton, J. E., Bungay, H. K., Arrivé, L., Ba‐Ssalamah, A., Grigoriadis, A., et al. (2021) · European Radiology · doi:10.1007/s00330-021-08333-7 · Cited by 4
Self-citationPhenotypes of Primary Sclerosing Cholangitis and Differential Diagnosis
Horwich, B., & Dieterich, D. T. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.07.006 · Cited by 3
AL-Oudat, M. A., Oudat, M. A., Migdady, H., Al-Munaizel, T., Mahmoud, M., & Jaafreh, S. (2020) · Research Square · doi:10.21203/rs.3.rs-106936/v1 · Cited by 3
“Also [40] suggested an approach to assess the biliary duct via MRI and MRCP images similarly to what was introduced by [41].”
Assessment of variations in intrahepatic bile duct by magnetic resonance cholangiopancreatography
Arslan, M., Ahmad, A., Qudoos, A., Iqbal, I., Hussain, M. T., & Amjad, U. (2023) · International Journal of Health Sciences · doi:10.53730/ijhs.v7ns1.14216
Ślósarz, T., Kaczorowski, R., Forenc, T., Pelczarska, A., Krupa, P. M., Witkowski, M., Mejza, P., & Kaczorowska, A. (2024) · Quality in Sport · doi:10.12775/qs.2024.24.54844
“SdPSC can progress to large duct PSC, occurring in 33-55% of cases[16,17].”
BackgroundPrimary Sclerosing Cholangitis
Hsu, R., Leung, P. S. C., Invernizzi, P., & Gershwin, M. E. (2024) · Springer eBooks · doi:10.1007/978-3-031-69895-8_61
Selvaraj, E. A., Ba-Ssalamah, A., Poetter‐Lang, S., Paun, B., Ridgway, G. R., Beyer, C., Andersson, A., Brady, M., Pansini, M., Culver, E. L., et al. (2026) · BMC Medical Imaging · doi:10.1186/s12880-026-02242-1
“…monitoring and its potential as an endpoint in antifibrotic drug trials for PSC. Early stages of PSC can be difficult to detect with liver biochemistry or qualitative MRCP [51, 52, but studies using contrast enhanced MRI found signs of peribiliary enhancement in these early phenotype PSC [53].”
Demystifying Idiopathic Adulthood Ductopenia: Diagnosis and Differential Diagnosis
Jing, H., Du, X., & Wang, H. L. (2026) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000531 · Cited by 1
A call for action: The need to quantify the “-itis” in primary sclerosing cholangitis
Eaton, J. E., Erickson, B. J., & Venkatesh, S. K. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.05.013
Self-citation
Metadata
- Authors
- Kozaka, K., Sheedy, S. P., Eaton, J. E., Venkatesh, S. K., & Heiken, J. P.
- Affiliations
- Kanazawa University (JP)
- Mayo Clinic (US)
- Corresponding author
- Heiken, Jay P.
- Venue
- Abdominal Radiology
- Published
- 2020-05-16
- Volume
- 45
- Issue
- 8
- Pages
- 2388-2399
- ISSN
- 2366-004X (ISSN-L)
- 2366-0058
- OpenAlex
- W3025728252
- Cited by
- 17
- References
- 29
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 2
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Abdominal Radiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- magnetic resonance cholangiopancreatography, disease progression, liver donors
- MeSH terms
- Bile Ducts, Cholangiopancreatography, Endoscopic Retrograde, Humans, Magnetic Resonance Imaging, Cholangitis, Sclerosing, Cholangiopancreatography, Magnetic Resonance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.